The VWD-Woman Study
We're sorry. This study is closed and no longer recruiting participants.
STUDY BASICS
Do you have von Willebrand disease and are pregnant? You may be able to participate in a study to examine the effectiveness of two different approaches to reduce blood loss at delivery. Participation involves 5 visits over 8 weeks. Compensation is provided.
IRB: STUDY20030186
- Prospective, Randomized Trial Comparing Recombinant von Willebrand Factor (rVWF) Plus Tranexamic Acid (TA) vs. rVWF Alone to Reduce Postpartum Hemorrhage in Women with von Willebrand Disease: The VWD-Woman TrialMEET THE RESEARCHER

Margaret V. Ragni
Margaret V. Ragni, MD, MPH, is a Professor of Medicine in the Division of Hematology/Oncology and a Professor of Clinical and Translational Science at the University of Pittsburgh. A graduate of the University of Pittsburgh, Dr. Ragni’s research interests include congenital hemostasis and thrombosis disorders.